SCHEMBL18180941

SCHEMBL18180941

CNCc1ccc(C(=N)OC(=N)c2nc(-c3ccc(S(=O)(=O)NCCO)cc3)cnc2N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 17/20 0.54
▸ GSK3B P49841 3/20 0.47
▸ CCNE2 O96020 2/20 0.47
▸ CCNE1 P24864 2/20 0.47
▸ CDK2 P24941 2/20 0.47
▸ ATRIP Q8WXE1 1/20 0.42
▸ PRKDC P78527 3/20 0.41
▸ ATM Q13315 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ KIT P10721 1/20 0.41
▸ SERPINA2 P20848 1/20 0.41
▸ PIK3R1 P27986 1/20 0.41
▸ FLT4 P35916 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ MAP3K9 P80192 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18180908 0.85 ATR (0.56) ATRGSK3BATRIPPRKDCATM
SCHEMBL18177406 0.83 SCN2A (0.38) ATRGSK3BCCNE2CCNE1CDK2
SCHEMBL13138298 0.83 ATR (0.52) ATRGSK3BPRKDCATMJAK2
SCHEMBL18180865 0.82 ATR (0.61) ATRGSK3BPRKDCATMJAK2
SCHEMBL18180887 0.82 ATR (0.59) ATRGSK3BCCNE2CCNE1CDK2
SCHEMBL16491612 0.81 ATR (0.58) ATRGSK3BPRKDCATMJAK2
SCHEMBL18180976 0.80 ATR (0.51) ATRGSK3BPRKDCATMJAK2
SCHEMBL18180944 0.80 ATR (0.57) ATRGSK3BCCNE2CCNE1CDK2
SCHEMBL13138295 0.80 ATR (0.52) ATRGSK3BPRKDCATMJAK2
SCHEMBL20432976 0.78 ATR (0.55) ATRGSK3BPRKDCATMJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885GSK3B 216/4885CCNE2 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback